Mucke Hermann A M
HM Pharma Consultancy, Wien, Austria.
Curr Opin Investig Drugs. 2006 Sep;7(9):792-8.
Failure of the cardiovascular system is the main reason for mortality in industrialized countries, and is a major cause of chronic morbidity. As most of the numerous ways in which it can fail will manifest in the second half of life and are exacerbated by old age, this situation is not likely to change in the near future unless fundamentally new ways of treating or preventing hypertension, atherosclerosis, myocardial infarction, chronic heart failure and cardiac arrhythmia are found. This prospect keeps the pharmaceutical industry on a constant, intense search for new therapeutic targets, new drugs, and new ways to identify such targets and drugs, as well as monitoring patient responses to drugs. This summary highlights the most interesting developments seen in cardiovascular and renal patents (other than those claiming formulations or combinations of known drugs) published during the first half of 2006.
在工业化国家，心血管系统衰竭是导致死亡的主要原因，也是慢性发病的主要因素。由于心血管系统出现故障的众多方式大多会在人生后半段显现出来，并且会因年老而加剧，所以除非找到治疗或预防高血压、动脉粥样硬化、心肌梗死、慢性心力衰竭和心律失常的全新方法，否则这种情况在近期内不太可能改变。这一前景促使制药行业持续、深入地寻找新的治疗靶点、新药，以及识别此类靶点和药物的新方法，同时监测患者对药物的反应。本综述重点介绍了2006年上半年公布的心血管和肾脏专利（不包括那些声称是已知药物的制剂或组合的专利）中最引人关注的进展。
